Arrowhead Pharmaceuticals

Filed a patent for "lipid conjugates for the delivery of therapeutic agents to adipose tissue" on Fri, January 6, 2023

Filed a patent for "rnai agents for inhibiting influenza viral gene expression, compositions thereof, and methods of use" on Fri, January 13, 2023

Filed a patent for "belt reactor manufacturing process for oligomer synthesis" on Wed, February 1, 2023

Filed a patent for "optimized rnai agents for inhibiting expression of coronavirus (cov) viral genomes, compositions thereof, and methods of use" on Thu, February 2, 2023

Filed a patent for "rnai agents for inhibiting expression of thymic stromal lymphopoietin (tslp), compositions thereof, and methods of use" on Wed, February 15, 2023

Filed a patent for "rnai agents for inhibiting influenza viral gene expression, compositions thereof, and methods of use" on Thu, March 2, 2023

Filed a patent for "rnai agents for inhibiting expression of proprotein convertase subtilisin kexin 9 (pcsk9), pharmaceutical compositions thereof, and methods of use" on Thu, March 2, 2023

Filed a patent for "rnai agents for inhibiting expression of mitochondrial amidoxime reducing component 1 (marc1), pharmaceutical compositions thereof, and methods of use" on Thu, March 16, 2023

Filed a patent for "rnai agents for inhibiting expression of ataxin-2 (atxn2), compositions thereof, and methods of use" on Fri, March 17, 2023

Filed a patent for "rnai agents for inhibiting expression of complement factor b (cfb), pharmaceutical compositions thereof, and methods of use" on Tue, March 21, 2023

Filed a patent for "rnai agents for inhibiting influenza a viral gene expression, compositions thereof, and methods of use" on Fri, April 28, 2023

Filed a patent for "metabolically stabilized carbohydrate targeting ligands for oligonucleotide conjugates" on Wed, May 31, 2023

Filed a patent for "hepatic delivery platforms for multimeric rnai agent conjugates and methods of use thereof" on Wed, May 31, 2023

Filed a patent for "rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)" on Thu, July 28, 2022

Filed a patent for "methods for the treatment of angptl3-related diseases and disorders" on Mon, August 22, 2022

Filed a patent for "treatment of a non-alcoholic fatty liver disease" on Mon, August 29, 2022

Filed a patent for "methods for the treatment of angptl3-related diseases and disorders" on Tue, September 20, 2022

Filed a patent for "rnai agents for inhibiting expression of coronavirus (cov) viral genomes, compositions thereof, and methods of use" on Tue, September 20, 2022

Filed a patent for "rnai agents for inhibiting expression of xanthine dehydrogenase (xdh), pharmaceutical compositions thereof, and methods of use" on Thu, May 4, 2023

Filed a patent for "rnai agents for inhibiting expression of matrix metalloproteinase 7 (mmp7), compositions thereof, and methods of use" on Thu, August 24, 2023

Filed a patent for "rnai agents for inhibiting expression of complement component c3 (c3), pharmaceutical compositions thereof, and methods of use" on Thu, October 27, 2022

Filed a patent for "rnai agents for inhibiting expression of xanthine dehydrogenase (xdh), pharmaceutical compositions thereof, and methods of use" on Thu, April 27, 2023

Filed a patent for "methods for the treatment of angptl3-related diseases and disorders" on Wed, November 9, 2022

Filed a patent for "rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)" on Thu, October 12, 2023

Filed a patent for "integrin ligands and uses thereof" on Thu, March 7, 2024